Meilleure Health International Industry Group Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Meilleure Health International Industry Group.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Trade Distributors earnings growth	6.7%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Meilleure Health International Industry Group's (HKG:2327) Shareholders May Want To Dig Deeper Than Statutory Profit

Oct 04

Earnings Not Telling The Story For Meilleure Health International Industry Group Limited (HKG:2327) After Shares Rise 34%

Sep 05

Meilleure Health International Industry Group (HKG:2327) Has A Somewhat Strained Balance Sheet

Aug 30

Meilleure Health International Industry Group Limited's (HKG:2327) 31% Share Price Plunge Could Signal Some Risk

Jul 19

Meilleure Health International Industry Group (HKG:2327) Will Be Hoping To Turn Its Returns On Capital Around

Jun 17

Optimistic Investors Push Meilleure Health International Industry Group Limited (HKG:2327) Shares Up 32% But Growth Is Lacking

May 03

Meilleure Health International Industry Group's (HKG:2327) Earnings Are Of Questionable Quality

Apr 04

Some Confidence Is Lacking In Meilleure Health International Industry Group Limited (HKG:2327) As Shares Slide 30%

Feb 28

Returns Are Gaining Momentum At Meilleure Health International Industry Group (HKG:2327)

Jan 23

Returns At Meilleure Health International Industry Group (HKG:2327) Appear To Be Weighed Down

Aug 17

Investors Met With Slowing Returns on Capital At Meilleure Health International Industry Group (HKG:2327)

Oct 18

Is Meilleure Health International Industry Group (HKG:2327) A Risky Investment?

Sep 06

Investors Will Want Meilleure Health International Industry Group's (HKG:2327) Growth In ROCE To Persist

Jul 12

Does Meilleure Health International Industry Group (HKG:2327) Have A Healthy Balance Sheet?

Sep 09

Meilleure Health International Industry Group (HKG:2327) Shareholders Will Want The ROCE Trajectory To Continue

May 15

Meilleure Health International Industry Group (HKG:2327) Seems To Use Debt Rather Sparingly

Apr 18

Did You Miss Meilleure Health International Industry Group's (HKG:2327) Impressive 124% Share Price Gain?

Jan 29

Here's What We Think About Meilleure Health International Industry Group's (HKG:2327) CEO Pay

Dec 08

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Meilleure Health International Industry Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2327 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	84	31	56	56	N/A
3/31/2024	107	36	-41	-40	N/A
12/31/2023	129	41	-137	-136	N/A
9/30/2023	130	33	-123	-122	N/A
6/30/2023	130	25	-109	-108	N/A
3/31/2023	125	22	-33	-32	N/A
12/31/2022	120	18	42	43	N/A
9/30/2022	148	23	42	46	N/A
6/30/2022	177	28	43	49	N/A
3/31/2022	215	44	-24	-17	N/A
12/31/2021	253	60	-90	-83	N/A
9/30/2021	263	72	-27	-24	N/A
6/30/2021	273	84	35	36	N/A
3/31/2021	269	84	53	53	N/A
12/31/2020	265	83	70	71	N/A
9/30/2020	262	32	11	11	N/A
6/30/2020	259	-19	-49	-48	N/A
3/31/2020	247	-19	-12	-12	N/A
12/31/2019	235	-20	25	25	N/A
9/30/2019	221	31	74	74	N/A
6/30/2019	208	83	123	123	N/A
3/31/2019	219	82	70	70	N/A
12/31/2018	231	81	18	18	N/A
9/30/2018	181	81	-40	-38	N/A
6/30/2018	132	81	-98	-94	N/A
3/31/2018	101	81	N/A	-79	N/A
12/31/2017	69	80	N/A	-63	N/A
9/30/2017	83	60	N/A	-177	N/A
6/30/2017	97	40	N/A	-291	N/A
3/31/2017	82	37	N/A	-276	N/A
12/31/2016	67	34	N/A	-261	N/A
12/31/2015	76	10	N/A	0	N/A
9/30/2015	17	-1	N/A	-45	N/A
6/30/2015	13	0	N/A	-21	N/A
3/31/2015	9	2	N/A	3	N/A
12/31/2014	16	1	N/A	29	N/A
9/30/2014	22	0	N/A	54	N/A
6/30/2014	29	44	N/A	63	N/A
3/31/2014	35	89	N/A	72	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2327's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2327's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2327's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2327's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2327's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2327's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/21 10:48
End of Day Share Price	2025/01/21 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Meilleure Health International Industry Group Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Li Wu	Tianfeng Securities Brokerage Co., Ltd

Meilleure Health International Industry Group Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Meilleure Health International Industry Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Recent updates

Executive Co-Chairman of the Board recently bought HK$432k worth of stock

Executive Co-Chairman of the Board recently bought HK$541k worth of stock

Executive Co-Chairman of the Board recently bought HK$1.2m worth of stock

Executive Co-Chairman of the Board recently bought HK$245k worth of stock

Meilleure Health International Industry Group's (HKG:2327) Shareholders May Want To Dig Deeper Than Statutory Profit

First half 2024 earnings released: EPS: HK$0.002 (vs HK$0.004 in 1H 2023)

Now 21% undervalued

Executive Co-Chairman of the Board recently bought HK$432k worth of stock

New major risk - Revenue and earnings growth

Earnings Not Telling The Story For Meilleure Health International Industry Group Limited (HKG:2327) After Shares Rise 34%

Executive Co-Chairman of the Board recently bought HK$715k worth of stock

Meilleure Health International Industry Group (HKG:2327) Has A Somewhat Strained Balance Sheet

New minor risk - Share price stability

Meilleure Health International Industry Group Limited to Report First Half, 2024 Results on Aug 31, 2024

Meilleure Health International Industry Group Limited's (HKG:2327) 31% Share Price Plunge Could Signal Some Risk

Executive Co-Chairman of the Board recently bought HK$592k worth of stock

Meilleure Health International Industry Group (HKG:2327) Will Be Hoping To Turn Its Returns On Capital Around

Executive Co-Chairman of the Board recently bought HK$485k worth of stock

Optimistic Investors Push Meilleure Health International Industry Group Limited (HKG:2327) Shares Up 32% But Growth Is Lacking

Executive Co-Chairman of the Board recently bought HK$119k worth of stock

Meilleure Health International Industry Group Limited Announces Board and Committees Changes

Meilleure Health International Industry Group's (HKG:2327) Earnings Are Of Questionable Quality

Full year 2023 earnings released: EPS: HK$0.01 (vs HK$0.004 in FY 2022)

Dividend reduced to HK$0.004

Meilleure Health International Industry Group Limited, Annual General Meeting, Jun 27, 2024

Meilleure Health International Industry Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 20 August 2024

Meilleure Health International Industry Group Limited to Report Fiscal Year 2023 Final Results on Mar 28, 2024

Some Confidence Is Lacking In Meilleure Health International Industry Group Limited (HKG:2327) As Shares Slide 30%

Now 31% undervalued after recent price drop

Returns Are Gaining Momentum At Meilleure Health International Industry Group (HKG:2327)

Executive Co-Chairman of the Board recently bought HK$135k worth of stock

Executive Co-Chairman of the Board recently bought HK$133k worth of stock

Executive Co-Chairman of the Board recently bought HK$251k worth of stock

First half 2023 earnings released: EPS: HK$0.004 (vs HK$0.003 in 1H 2022)

New minor risk - Earnings quality

Returns At Meilleure Health International Industry Group (HKG:2327) Appear To Be Weighed Down

Meilleure Health International Industry Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Meilleure Health International Industry Group Limited to Report First Half, 2023 Results on Aug 31, 2023

Upcoming dividend of HK$0.016 per share at 5.4% yield

Executive Co-Chairman of the Board recently bought HK$274k worth of stock

Meilleure Health International Industry Group Limited Approves Final Dividend

Executive Co-Chairman of the Board recently bought HK$153k worth of stock

Executive Co-Chairman of the Board recently bought HK$145k worth of stock

Full year 2022 earnings released: EPS: HK$0.004 (vs HK$0.014 in FY 2021)

Executive Co-Chairman of the Board recently bought HK$1.1m worth of stock

Executive Co-Chairman of the Board recently bought HK$272k worth of stock

Executive Co-Chairman of the Board recently bought HK$325k worth of stock

Less than half of directors are independent

Executive Co-Chairman of the Board recently bought HK$169k worth of stock

Investors Met With Slowing Returns on Capital At Meilleure Health International Industry Group (HKG:2327)

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Is Meilleure Health International Industry Group (HKG:2327) A Risky Investment?

First half 2022 earnings released: EPS: HK$0.003 (vs HK$0.01 in 1H 2021)

Meilleure Health International Industry Group Limited to Report First Half, 2022 Results on Aug 26, 2022

Investors Will Want Meilleure Health International Industry Group's (HKG:2327) Growth In ROCE To Persist

Meilleure Health International Industry Group Limited, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Executive Co-Chairman of the Board recently bought HK$305k worth of stock

Full year 2021 earnings released: EPS: HK$0.014 (vs HK$0.02 in FY 2020)

Executive Co-Chairman of the Board recently bought HK$1.1m worth of stock

Independent Non-Executive Director recently sold HK$142k worth of stock

Does Meilleure Health International Industry Group (HKG:2327) Have A Healthy Balance Sheet?

First half 2021 earnings released: EPS HK$0.01 (vs HK$0.01 in 1H 2020)

Executive Co-Chairman of the Board recently bought HK$1.7m worth of stock

Meilleure Health International Industry Group (HKG:2327) Shareholders Will Want The ROCE Trajectory To Continue

Full year 2020 earnings released: EPS HK$0.02 (vs HK$0.005 loss in FY 2019)

Meilleure Health International Industry Group (HKG:2327) Seems To Use Debt Rather Sparingly

Executive Co-Chairman of the Board recently bought HK$441k worth of stock

Full year 2020 earnings released: EPS HK$0.02 (vs HK$0.005 loss in FY 2019)

Meilleure Health International Industry Group Limited to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day high: HK$0.69

Did You Miss Meilleure Health International Industry Group's (HKG:2327) Impressive 124% Share Price Gain?

New 90-day high: HK$0.57